Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp57569_8k.htm |
| EX-99.2 - EXHIBIT 99.2 - Shire plc | dp57569_ex9902.htm |
Exhibit 99.1
| Press Release |  |
| www.shire.com |
Director/PDMR Share Dealings
June 30, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from April 1 to June 30, 2015.
| Type of Security (1) | Number of Shares/ADSs | ||
| Dominic Blakemore | Shares | 114 | |
| William Burns | Shares | 126 | |
| Dr. Steven Gillis | ADSs | 40 | |
| Dr. David Ginsburg | ADSs | 36 | |
| David Kappler | Shares | 126 | |
| Susan Kilsby | ADSs | 133 | |
| Anne Minto | Shares | 128 | |
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £51.05 per Share and $241.4578 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX